Roderick O'DAy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Roderick O'DAy has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Bertil Damato
Ocular Oncology Service, Moorfields Eye Hospital, London, United Kingdom
3 shared publications - Daniel Barthelmes
Department of Ophthalmology, Hospital of Zurich, University of Zurich, 8091 Zurich, Switzerland
3 shared publications - Kelsey Andrea Roelofs
Department of Ophthalmology and Visual Sciences, University of Alberta
3 shared publications - Lotte S. Fog
Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) Sydney New South Wales Australia
3 shared publications - Mandeep S. Sagoo
Ocular Oncology Service, Moorfields Eye Hospital NHS Foundation Trust, London, UK
3 shared publications - Amit K. Arora
Ocular Oncology Service, Moorfields Eye Hospital, London EC1V 2PD, UK
2 shared publications
Latest Publications
- 29 December 2025
- Published by Elsevier in Ophthalmology Retina
Adjuvant Chemotherapy in Retinoblastoma with Postlaminar Optic Nerve Invasion
- 29 December 2025
- Published by Elsevier in Ophthalmology Retina
Adjuvant Chemotherapy in Retinoblastoma with Postlaminar Optic Nerve Invasion
- 26 May 2024
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 59 (5) , e525-e533
The Fight Tumour Blindness Registry: Efficient capture of high-quality real-world data in uveal melanoma
- 26 May 2024
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 59 (5) , e525-e533
The Fight Tumour Blindness Registry: Efficient capture of high-quality real-world data in uveal melanoma
- Open Access
- 4 April 2024
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 59 (6) , e775-e783
Apical dose versus volume dose of Ruthenium-106 brachytherapy for uveal melanoma
- 4 April 2024
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 59 (6) , e775-e783
Open AccessApical dose versus volume dose of Ruthenium-106 brachytherapy for uveal melanoma
- 17 October 2023
- Published by Elsevier in Ophthalmology Retina
- Vol. 8 (4) , 325-330
Globe Salvage and Vision Preservation by Neoadjuvant Darovasertib and Crizotinib in Uveal Melanoma
- 17 October 2023
- Published by Elsevier in Ophthalmology Retina
- Vol. 8 (4) , 325-330
Globe Salvage and Vision Preservation by Neoadjuvant Darovasertib and Crizotinib in Uveal Melanoma
- Open Access
- 5 March 2022
- Published by Springer Nature in Journal of Ophthalmic Inflammation and Infection
- Vol. 12 (1) , 1-7
Ultra-low dose external beam radiotherapy for presumed choroidal lymphoma: a case report
Primary choroidal lymphoma is a rare, slowly progressive intraocular malignancy. Most are low grade B cell lymphomas, often involving tissues adjacent to the choroid such as the subconjunctival space, lacrimal gland or orbit. Ideally, these lesions are biopsied to establish histopathological diagnosis. The most accessible ocular structure is biopsied. Obtaining tissue by transvitreal choroidal biopsy imparts a small but significant risk of ocular morbidity, including the need for multiple surgeries, retinal detachment and vision loss.External beam radiotherapy (EBRT) is a common and effective treatment of low-grade lymphomas. EBRT has been found to very successfully treat primary marginal zone lymphomas of the ocular adnexa, which are typically of the same cell type as most primary choroid lymphomas. Ultra-low dose EBRT, most commonly using a total dose of 4 Gy, has been shown to be as effective as higher doses of radiotherapy for follicular or marginal zone lymphomas. The use of this low dose regimen for conjunctival lymphomas has been recently explored. The role of EBRT, and especially ultra-low dose EBRT, for treatment of primary choroidal lymphoma has been confined to case reports.We describe a case of presumed primary choroidal lymphoma diagnosed on clinical findings alone as the risks of ocular biopsy were deemed too high, and report outcome following treatment with ultra-low dose EBRT.
- 5 March 2022
- Published by Springer Nature in Journal of Ophthalmic Inflammation and Infection
- Vol. 12 (1) , 1-7
Open AccessUltra-low dose external beam radiotherapy for presumed choroidal lymphoma: a case report
Primary choroidal lymphoma is a rare, slowly progressive intraocular malignancy. Most are low grade B cell lymphomas, often involving tissues adjacent to the choroid such as the subconjunctival space, lacrimal gland or orbit. Ideally, these lesions are biopsied to establish histopathological diagnosis. The most accessible ocular structure is biopsied. Obtaining tissue by transvitreal choroidal biopsy imparts a small but significant risk of ocular morbidity, including the need for multiple surgeries, retinal detachment and vision loss.External beam radiotherapy (EBRT) is a common and effective treatment of low-grade lymphomas. EBRT has been found to very successfully treat primary marginal zone lymphomas of the ocular adnexa, which are typically of the same cell type as most primary choroid lymphomas. Ultra-low dose EBRT, most commonly using a total dose of 4 Gy, has been shown to be as effective as higher doses of radiotherapy for follicular or marginal zone lymphomas. The use of this low dose regimen for conjunctival lymphomas has been recently explored. The role of EBRT, and especially ultra-low dose EBRT, for treatment of primary choroidal lymphoma has been confined to case reports.We describe a case of presumed primary choroidal lymphoma diagnosed on clinical findings alone as the risks of ocular biopsy were deemed too high, and report outcome following treatment with ultra-low dose EBRT.
- 13 February 2022
- Published by Taylor & Francis in Clinical and Experimental Optometry
- Vol. 106 (3) , 271-275
The MOLES system to guide the management of melanocytic choroidal tumours: can optometrists apply it?
Although melanocytic choroidal tumours of the choroid are a common eye pathology, no standardised protocol exists for their management in the community.Choroidal naevi are found in approximately 6%...
- 13 February 2022
- Published by Taylor & Francis in Clinical and Experimental Optometry
- Vol. 106 (3) , 271-275
The MOLES system to guide the management of melanocytic choroidal tumours: can optometrists apply it?
Although melanocytic choroidal tumours of the choroid are a common eye pathology, no standardised protocol exists for their management in the community.Choroidal naevi are found in approximately 6%...
- 2 March 2021
- Published by Taylor & Francis in Clinical and Experimental Optometry
- Vol. 104 (8) , 854-858
Estimating malignancy risk of melanocytic choroidal tumours detected in the Australian National Eye Health Survey
Clinical relevance: The malignant potential of choroidal melanocytic tumours detected incidentally in the community is thought to be low, but this has not been assessed using a validated screening tool. An accurate characterisation of the malignant potential of these lesions has implications for resource allocation, service provision, education, and training. Background: MOLES (Mushroom shape, Orange Pigment, Large size, Enlargement, and Subretinal fluid) categorises tumours as ‘common naevus’, ‘low-risk naevus’, ‘high-risk naevus’, and ‘probable melanoma’. The MOLES system recommends that patients with common naevi (score = 0) undergo review by a community optometrist every two years, ideally with sequential colour photography. For the remaining patients (score ≥ 1), specialist imaging and assessment are recommended, with referral triaged as non-urgent for patients with low-risk (score = 1) or high-risk naevi (score = 2) and urgent for patients with probable melanoma (score > 2). Methods: Lesions flagged as choroidal melanocytic tumours on retinal photographs taken during the Australian National Eye Health Survey were retrospectively analysed by an ocular oncologist. Each lesion was assigned a MOLES score and categorised as common, low-risk, high-risk or probable melanoma. Results: Seventy-seven choroidal naevi were identified. Seventy-five (97%) of the choroidal naevi were categorised as common naevi, with a MOLES score of 0. Two (3%) choroidal naevi had a score of 1 and diagnosed as low-risk naevi due to their size. No naevi had a score of 2 or more. Conclusion: All choroidal naevi detected in this nationally representative population survey were innocuous. This suggests that the vast majority of choroidal melanocytic tumours that are incidentally detected in Australia can be managed in primary eye care settings without the need for specialist referral. MOLES provides a simple evidence-based method for choroidal naevi assessment in primary care.
- 2 March 2021
- Published by Taylor & Francis in Clinical and Experimental Optometry
- Vol. 104 (8) , 854-858
Estimating malignancy risk of melanocytic choroidal tumours detected in the Australian National Eye Health Survey
Clinical relevance: The malignant potential of choroidal melanocytic tumours detected incidentally in the community is thought to be low, but this has not been assessed using a validated screening tool. An accurate characterisation of the malignant potential of these lesions has implications for resource allocation, service provision, education, and training. Background: MOLES (Mushroom shape, Orange Pigment, Large size, Enlargement, and Subretinal fluid) categorises tumours as ‘common naevus’, ‘low-risk naevus’, ‘high-risk naevus’, and ‘probable melanoma’. The MOLES system recommends that patients with common naevi (score = 0) undergo review by a community optometrist every two years, ideally with sequential colour photography. For the remaining patients (score ≥ 1), specialist imaging and assessment are recommended, with referral triaged as non-urgent for patients with low-risk (score = 1) or high-risk naevi (score = 2) and urgent for patients with probable melanoma (score > 2). Methods: Lesions flagged as choroidal melanocytic tumours on retinal photographs taken during the Australian National Eye Health Survey were retrospectively analysed by an ocular oncologist. Each lesion was assigned a MOLES score and categorised as common, low-risk, high-risk or probable melanoma. Results: Seventy-seven choroidal naevi were identified. Seventy-five (97%) of the choroidal naevi were categorised as common naevi, with a MOLES score of 0. Two (3%) choroidal naevi had a score of 1 and diagnosed as low-risk naevi due to their size. No naevi had a score of 2 or more. Conclusion: All choroidal naevi detected in this nationally representative population survey were innocuous. This suggests that the vast majority of choroidal melanocytic tumours that are incidentally detected in Australia can be managed in primary eye care settings without the need for specialist referral. MOLES provides a simple evidence-based method for choroidal naevi assessment in primary care.
- Open Access
Detecting Progression of Melanocytic Choroidal Tumors by Sequential Imaging: Is Ultrasonography Necessary?
Purpose: To determine if ultrasonography is necessary to detect progression of choroidal melanocytic tumors undergoing sequential multi-modal imaging with color photography, autofluorescence (AF) and optical coherence tomography (OCT). Methods: All patients with choroidal melanoma undergoing treatment at Moorfields Eye Hospital between January 2016 and March 2020 were reviewed to identify those with treatment deferred by ≥2 months. Tumors that showed progression prior to treatment, defined as an increase in (a) basal dimensions (b) thickness (c) orange pigment and/or (d) sub-retinal fluid, were included. Mushroom shape, Orange pigment, Large size, Enlargement and Sub-retinal fluid (MOLES) scores were assigned to all tumors at earliest date and date of treatment. Results: A total of 99 patients with a mean age of 66 years (range: 26–90) were included. The initial MOLES score was 1 in 2 cases, 2 in 23 cases, and ≥3 in 74 cases. Progression was detected with sequential color photography alone in 100% of MOLES 1/2 and 97% of lesions with a MOLES score of ≥3. When findings on AF and OCT were included, sensitivity for detecting subtle change without ultrasonography improved to 100% for MOLES 3 and 97% for MOLES 4/5. Only one patient included in this study had an isolated increase in thickness that may have been missed had sequential ultrasonography not been performed. Overall, the sensitivity for detecting progression with color photographs alone was 97% (95% CI 93–100%) and increased to 99% (95% CI 97–100%) by including autofluorescence and OCT. Conclusions: Monitoring of choroidal nevi, particularly those classified as MOLES 1 or 2 (i.e., low-risk or high-risk naevi), can be accomplished safely without the need for ultrasonography. The findings of this study may remove barriers to the implementation of tele-oncology clinics for the monitoring of choroidal melanocytic tumors.
Open AccessDetecting Progression of Melanocytic Choroidal Tumors by Sequential Imaging: Is Ultrasonography Necessary?
Purpose: To determine if ultrasonography is necessary to detect progression of choroidal melanocytic tumors undergoing sequential multi-modal imaging with color photography, autofluorescence (AF) and optical coherence tomography (OCT). Methods: All patients with choroidal melanoma undergoing treatment at Moorfields Eye Hospital between January 2016 and March 2020 were reviewed to identify those with treatment deferred by ≥2 months. Tumors that showed progression prior to treatment, defined as an increase in (a) basal dimensions (b) thickness (c) orange pigment and/or (d) sub-retinal fluid, were included. Mushroom shape, Orange pigment, Large size, Enlargement and Sub-retinal fluid (MOLES) scores were assigned to all tumors at earliest date and date of treatment. Results: A total of 99 patients with a mean age of 66 years (range: 26–90) were included. The initial MOLES score was 1 in 2 cases, 2 in 23 cases, and ≥3 in 74 cases. Progression was detected with sequential color photography alone in 100% of MOLES 1/2 and 97% of lesions with a MOLES score of ≥3. When findings on AF and OCT were included, sensitivity for detecting subtle change without ultrasonography improved to 100% for MOLES 3 and 97% for MOLES 4/5. Only one patient included in this study had an isolated increase in thickness that may have been missed had sequential ultrasonography not been performed. Overall, the sensitivity for detecting progression with color photographs alone was 97% (95% CI 93–100%) and increased to 99% (95% CI 97–100%) by including autofluorescence and OCT. Conclusions: Monitoring of choroidal nevi, particularly those classified as MOLES 1 or 2 (i.e., low-risk or high-risk naevi), can be accomplished safely without the need for ultrasonography. The findings of this study may remove barriers to the implementation of tele-oncology clinics for the monitoring of choroidal melanocytic tumors.
- Open Access
- 28 January 2020
- Published by S. Karger AG in Ocular Oncology and Pathology
- Vol. 6 (4) , 275-279
Intra-Scleral Blue Nevus Arising within Oculodermal Melanocytosis: Melanoma or Not?
We report a 61-year-old female who presented to our service with recent growth of a thickened, pigmented, sub-conjunctival lesion within an area of ocular melanocytosis in her left eye. Lamellar sclerectomy was performed. Histopathological assessment revealed a localized melanocytic proliferation with features of blue nevus arising within the area of ocular melanocytosis. There was a small zone of cells showing cytological atypia and expansion of the scleral stroma. We believe this case to be the first report of intrascleral blue nevus arising within an area of ocular melanocytosis. Given the cytological atypia, the blue nevus may perhaps represent an intermediate stage within a progression from ocular melanocytosis towards melanoma. Patients with oculodermal melanocytosis merit regular long-term surveillance for early detection of melanoma, not only in the uvea, but also in the orbit and potentially the ocular surface.
- 28 January 2020
- Published by S. Karger AG in Ocular Oncology and Pathology
- Vol. 6 (4) , 275-279
Open AccessIntra-Scleral Blue Nevus Arising within Oculodermal Melanocytosis: Melanoma or Not?
We report a 61-year-old female who presented to our service with recent growth of a thickened, pigmented, sub-conjunctival lesion within an area of ocular melanocytosis in her left eye. Lamellar sclerectomy was performed. Histopathological assessment revealed a localized melanocytic proliferation with features of blue nevus arising within the area of ocular melanocytosis. There was a small zone of cells showing cytological atypia and expansion of the scleral stroma. We believe this case to be the first report of intrascleral blue nevus arising within an area of ocular melanocytosis. Given the cytological atypia, the blue nevus may perhaps represent an intermediate stage within a progression from ocular melanocytosis towards melanoma. Patients with oculodermal melanocytosis merit regular long-term surveillance for early detection of melanoma, not only in the uvea, but also in the orbit and potentially the ocular surface.